Scientific advisory board
DVM, Professor em. in Virology, Swedish University of Agricultural Sciences (SLU), Uppsala. Founder of Isconova AB and of it’s adjuvant technology (Iscomes; Matrix).
Doctor of technology, Professor of Microbiology, the Royal Institute of Technology (KTH) since 1988. Vice-President at KTH 1999-2001. Mathias Uhlén is a member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science, the European Molecular Biology Organisation (EMBO) and the Human Proteome Organisation (HUPO). Founder of a number of biotech companies such as Pyrosequencing (now Biotage), Affibody AB, Swe Tree Technologies AB and other.
PhD in veterinary pharmacology.
He is the author of a large number of scientific publications in pharmacology, microbiology and immunology with a focus on vaccine development. He has many years experience from industry, such as being responsible for R/D at Novartis Animal Health. He is a chairman in Moredun Scientific Ltd and GALVmed. He resides in Scotland.